Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Trowbridge

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Reviews in Allergy & Immunology|November 10, 2007
Innate immunity: a cutaneous perspectiveHeidi Goodarzi, Janet Trowbridge, Richard L Gallo
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growthAmanda S Büchau, Shin Morizane, Janet Trowbridge, et al.
The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Reviews in Allergy & Immunology|November 10, 2007
Innate immunity: a cutaneous perspectiveHeidi Goodarzi, Janet Trowbridge, Richard L Gallo
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growthAmanda S Büchau, Shin Morizane, Janet Trowbridge, et al.
The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
Pageof 1